In a recent clinical trial in patients with advanced solid tumors or lymphomas, CA170 had a favorable safety profile (up to 1200 mg BID) and a short half-life (comparing to antibody ICIs) and showed immune-modulating effects with tumor regression26. A recent study further confirmed that CA170 selectively inhibits PD-L1/L2 and VISTA pathways, and exhibits significant anti-tumor efficacy in murine colon and melanoma tumor models27. Here, VSIR is linked to neoplasm.